NASDAQ
Cellectar Biosciences, Inc. (CLRB)
♥ 405 Thanks from members
Cellectar Biosciences (CLRB) presents a polarized investment profile, balancing strong clinical milestones for iopofosine I 131 in Waldenström Macroglobulinemia and an oversubscribed $140 million financing package against persistent going concern risks and execution hurdles.